ARTICLE | Clinical News
Opdivo regulatory update
December 7, 2016 10:32 PM UTC
Bristol-Myers Squibb and Ono said Japan approved a label expansion for Opdivo nivolumab to include treatment of relapsed or refractory classical Hodgkin lymphoma. The humanized IgG4 mAb against PD-1 i...
BCIQ Target Profiles